Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Spain.
J Gastroenterol Hepatol. 2011 Mar;26 Suppl 2:12-6. doi: 10.1111/j.1440-1746.2010.06600.x.
Pancreatic insufficiency is a major consequence of pancreatic diseases leading to a loss of pancreatic parenchyma, obstruction of the main pancreatic duct, decreased pancreatic stimulation, or acid-mediated inactivation of pancreatic enzymes. In addition, gastrointestinal and pancreatic surgical resections are frequent causes. Clinical manifestations include abdominal cramps, steatorrhea and malnutrition. Malnutrition, the main contributing factor of weight loss, has been related to a high morbidity and mortality secondary to an increased risk of malnutrition-related complications and cardiovascular events. Assessments of exocrine pancreatic function, such as fecal fat quantification and (13) C-triglyceride breath test, are the method of choice for diagnosis. In clinical practice, high-risk patient populations include those with severe necrotizing pancreatitis, gastrointestinal and pancreatic surgery, cancer of pancreas head, and those with pancreatic calcifications. Apart from relief of maldigestion-related symptoms, the main goal of pancreatic enzyme substitution therapy is to ensure a normal nutritional status. Therapy of pancreatic insufficiency is based on the oral administration of exogenous pancreatic enzymes. Restriction of fat intake, though traditionally important in conventional treatment, should be reconsidered. Enzyme substitution therapy should ideally mimic the physiological pattern of pancreatic exocrine secretion, and pancreatic enzymes in the form of enteric-coated minimicrospheres are considered as the most elaborated commercially available enzyme preparations. In general, pancreatic exocrine insufficiency in patients after surgery may be managed similarly to patients with chronic pancreatitis. This review focuses on current perspectives in diagnosis and treatment of pancreatic exocrine insufficiency and practical suggestions on its clinical management.
胰腺外分泌功能不全是胰腺疾病的主要后果,导致胰腺实质丧失、主胰管阻塞、胰腺刺激减少或酸介导的胰腺酶失活。此外,胃肠道和胰腺的外科切除术也是常见的原因。临床表现包括腹痛、脂肪泻和营养不良。营养不良是体重减轻的主要因素,与营养不良相关并发症和心血管事件的风险增加相关的高发病率和死亡率有关。粪便脂肪定量和(13)C-甘油三酯呼气试验等胰腺外分泌功能评估是诊断的首选方法。在临床实践中,高危人群包括重症坏死性胰腺炎、胃肠道和胰腺手术、胰头癌以及胰腺钙化患者。除了缓解与消化不良相关的症状外,胰腺酶替代治疗的主要目标是确保正常的营养状态。胰腺外分泌功能不全的治疗基于口服外源性胰腺酶。尽管传统上限制脂肪摄入在常规治疗中很重要,但应重新考虑。酶替代治疗理想情况下应模拟胰腺外分泌分泌的生理模式,肠溶包衣微球形式的胰腺酶被认为是最精细的市售酶制剂。一般来说,手术后患者的胰腺外分泌功能不全可以类似于慢性胰腺炎患者的治疗。本文重点介绍胰腺外分泌功能不全的诊断和治疗的最新观点,并就其临床管理提出实用建议。